A new anti-mycobacterial agent, rifabutin

Kekkaku

Volumn 85, Issue 10, 2010, Pages 743-756

  Kurashima, Atsuyuki ^a   Mori, Toru ^b   Tomono, Yoshiro ^c   Abe, Sadahiro ^c   Nagaoka, Makoto ^d   Abe, Masaaki ^c  

^a Japan Anti Tuberculosis Association   (Japan)

^b JATA   (Japan)

^c PFIZER INC   (United States)

^d Pfizer Japan Inc   (Japan)

Author keywords

AIDS; Anti mycobacterial agent; HIV infection; Non tuberculous mycobacteriosis; Rifabutin; Tuberculosis

Indexed keywords

RIFABUTIN; TUBERCULOSTATIC AGENT;

COMPARATIVE STUDY; HUMAN; REVIEW; TUBERCULOSIS;

ANTIBIOTICS, ANTITUBERCULAR; HUMANS; RIFABUTIN; TUBERCULOSIS;

EID: 79952109322     PISSN: 00229776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. American Thoracic Society: Diagnostic standards and classification of tuberculosis in adults and children. Am J Respir Crit Care Med. 2000; 161: 1376-1395.
2. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of tuberculosis. Am J Respir Crit Care Med. 2003; 167: 603-662.
3. American Thoracic Society: Treatment of tuberculosis and tuberculosis infection in adults and children. Am J Respir Crit Care Med. 1994; 149: 1359-1374.
4. American Thoracic Society: Diagnosis and treatment of disease caused by nontuberculous mycobacteria. Am J Repir Crit Care Med. 1997; 156: s1-s25.
5. Ungheri D, Della Bruna C, Jabes D, et al.: LM427: further studies on the antimycobacterial activity. [abstr] 13th International Congress of Chemotherapy. Vienna, Aug 28-Sep 2, 1983.
6. Saito H, Sato K, Tomioka H: Comparative in vitro and in vivo activity of rifabutin and rifampicin against Mycobacterium avium complex. Tubercle. 1988; 69: 187-192.
7. The Sanford Guide to Antimicrobial Therapy, 37th ed. Table 12A(4) [Mycobacterium tuberculosis], 2007, 113.
8. Heifets LB, Iseman MD: Determination of in vitro susceptibility of mycobacteria to ansamycin. Am Rev Respir Dis. 1985; 132: 710-711. (Pubitemid 15247997)
9. Chien H-P, Yu M-C, Ong T-F, et al.: In vitro activity of rifabutin and rifampin against clinical isolates of Mycobacterium tuberculosis in Taiwan. J Formos Med Assoc. 2000; 99: 408-411. (Pubitemid 30399237)
10. Uzun M, Erturan Z, Anǧ Ö: Investigation of cross-resistance between rifampin and rifabutin in Mycobacterium tuberculosis complex strains. Int J Tuberc Lung Dis. 2002; 6: 164-165. (Pubitemid 34263709)
11. Senol G, Erbaycu A, Özsöz A: Incidence of cross resistance between rifampicin and rifabutin in Mycobacterium tuberculosis strains in Izmir, Turkey. J Chemother. 2005; 17: 380-384. (Pubitemid 41284775)
12. Williams DL, Spring L, Collins L, et al.: Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis. Antimicrob Agents Chemother. 1998; 42: 1853-1857. (Pubitemid 28311593)
13. Yuen LKW, Leslie D, Coloe PJ: Bacteriological and molecular analysis of rifampin-resistant Mycobacterium tuberculosis strains isolated in Australia. J Clin Microbiol. 1999; 37: 3844-3850.
14. Sintchenko V, Chew WK, Jelfs PJ, et al.: Mutations in rpoB gene and rifabutin susceptibility of multidrug-resistant Mycobacterium tuberculosis strains isolated in Australia. Pathology. 1999; 31: 257-260. (Pubitemid 29417609)
15. Cavusoglu C, Karaca-Derici Y, Bilgic A: In-vitro activity of rifabutin against rifampicin-resistant Mycobacterium tuberculosis isolates with known rpoB mutations. Clin Microbiol Infect. 2004; 10: 662-665. (Pubitemid 39077057)
16. Ramaswamy S, Musser JM: Molecular genetic basis of antimicrobial agent resistance in Mycobacterium tuberculosis: 1998 update. Tuberc Lung Dis. 1998; 79: 3-29. (Pubitemid 29050434)
17. Artsimovitch I, Vassylyev DG: Is it easy to stop RNA polymerase? Cell Cycle. 2006; 5: 399-404.
18. Campbell EA, Korzheva N, Mustaev A, et al.: Structural mechanism for rifampicin inhibition of bacterial RNA polymerase. Cell. 2001; 104: 901-912. (Pubitemid 32289282)
19. Yang B, Koga H, Ohno H, et al.: Relationship between antimycobacterial activities of rifampicin, rifabutin and KRM-1648 and rpoB mutations of Mycobacterium tuberculosis. J Antimicrob Chemother. 1998; 42: 621-628. (Pubitemid 28510620)
20. Artsimovitch I, Vassylyeva MN, Svetlov D, et al.: Allosteric modulation of the RNA polymerase catalytic reaction is an essential component of transcription control by rifamycins. Cell. 2005; 122: 351-363. (Pubitemid 41127138)
21. Ungheri D, Sanfilippo A: Activity of LM 427 Legionella spp,: In vitro study and intracellulare killing. 14th International Congress of Chemotherapy, Kyoto, University of Tokyo Press, Tokyo, 1985, 1917-1918.
22. Van der Awera T, Matsumoto T, Husson M: Intraphagocytic penetration of antibiotics. J Antimicrob Chemothr. 1988; 22: 185-192.
23. Gangadharam PRJ, Perumal VK, Jairam BT, et al.: Activity of rifabutin alone or in combination with clofazimine or ethambutol or both against acute and chronic experimental Mycobacterium intracellulare infections. Am Rev Respir Dis. 1987; 136: 329-333. (Pubitemid 18018528)
24. Cato A III, Cavanaugh J, Shi H, et al.: The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin. Clin Pharmacol Ther. 1998; 63: 414-421. (Pubitemid 28214964)
25. Polk RE, Brophy DF, Israel DS, et al.: Pharmacokinetic Interaction between Amprenavir and Rifabutin or Rifampin in Healthy Males. Antimicrob Agent Chemother. 2001; 45: 502-508. (Pubitemid 32105287)
26. Kraft WK, McCrea JB, Winchell GA, et al.: Indinavir and rifabutin drug interactions in healthy volunteers. J Clin Pharmacol. 2004; 44: 305-313. (Pubitemid 38233827)
27. Lefort A, Launay O, Carbon C: Uveitis associated with rifabutin prophylaxis and itraconazole therapy. Ann Intern Med. 1996; 125: 939-940. (Pubitemid 28363474)
28. DATRI (Division of AIDS Treatment Research Institute) Study Group: Coadministration of clarithromycin (CL) alters the concentration-time profile of rifabutin (RFB). 34th Interscience Conference on Antimicrobial Agents and Chemotherapy, Orlando. 1994, Abst. A2.
29. Trapnell CB, Narang PK, Li R, et al.: Increased plasma rifabutin levels with concomitant fluconazole therapy in HIVinfected patients. Ann Intern Med. 1996; 124: 573-576. (Pubitemid 26085059)
30. Moyle GJ, Buss NE, Goggin T, et al.: Interaction between saquinavir soft-gel and rifabutin in patients infected with HIV. Br J Clin Pharmacol. 2002; 54: 178-182. (Pubitemid 35024942)
31. Smith JA, Hardin TC, Patterson TF, et al.: Rifabutin (RIF) decreases itraconazole (ITRA) plasma levels in patients with HIV-infection. 2nd National Conference on Human Retroviruses and Related Infections, Washington. 1995, Abst. 126.
32. Salcedo J, Narang PK, Sweeny J, et al.: Alteration of dapsone metabolism by rifabutin in HIV (+) subjects. Clin Pharmacol Ther. 1996; 59: 158 (Abst. OI-B-3).
33. Borin MT, Chambers JH, Carel BJ, et al.: Pharmacokinetic study of the interaction between rifabutin and delavirdine mesylate in HIV-1 infected patients. Antiviral Res. 1997; 35: 53-63. (Pubitemid 27261206)
34. LeBel M, Masson E, Guilbert E, et al.: Effects of rifabutin and rifampicin on the pharmacokinetics of ethinylestradiol and norethindrone. J Clin Pharmacol. 1998; 38: 1042-1050. (Pubitemid 28524452)
35. DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents: Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescent. 2008, 1.